Ethics, Codes & Guidelines
PhRMA represents the nation’s leading biopharmaceutical research companies. Our success in developing and delivering medicines to help patients live longer and healthier lives depends on ethical relationships and behavior. Browse key Codes and Guidelines below, and visit our Resource Library for more.
U.S. Consensus Framework to Advance Health Equity & Ethical Collaboration
Designed as a forum for leading US health system stakeholders, the ongoing addition of key health stakeholders and the inclusion of diverse sector perspectives facilitates the establishment of best practices and high standards that center on the needs of patients and the promotion of health equity.
Press Release: Launch of U.S. Consensus Framework to Advance Health Equity & Ethical Collaboration
Representatives from the National Health Council (NHC), the National Medical Association (NMA), and the Pharmaceutical Researchers & Manufacturers Association (PhRMA) have launched an open initiative to advance health equity and ethical collaboration in the US health ecosystem.
Statement by IMC, AMIIF and PhRMA on Promoting Ethics and Business Integrity in Healthcare
As representatives of the pharmaceutical industry, we strongly support and are active leaders in the Business Ethics for APEC SMEs Initiative, the world’s largest public-private partnership to strengthen ethical business practices in the biopharmaceutical sector.
Code on Interactions With Health Care Professionals
Ethical relationships with healthcare professionals are critical to our mission of helping patients by developing and marketing new medicines.
Direct to Consumer Advertising Principles
In October 2018, PhRMA’s Board of Directors adopted measures to enhance the PhRMA Guiding Principles on Direct to Consumer Advertisements about Prescription Medicines.
Principles On Responsible Sharing of Truthful and Non-Misleading Information
In the era of data-driven medicine, where all parties seek more, not less, information about the safety, effectiveness, and value of treatments, fostering informed communications among all stakeholders is critical.
For a Healthier U.S.: Methods to Fight Prescription Abuse
We need a balanced approach that ensures appropriate access and use of prescription medicines by patients for legitimate medical needs under the direction and care of a licensed health care professional, but that also reduces the potential for misuse, abuse and diversion.
Principles on Interactions with Patient Organizations
Biopharmaceutical companies share many common interests with patient organizations including a common commitment to patients and a shared mission to discover cures and fight disease.
PhRMA Principles on Conduct of Clinical Trials
Developing new therapies to treat disease and to improve quality of life is a long and complex process. A critical part of that process is clinical research, the study of a pharmaceutical product in humans.
PhRMA Principles for Payment and Delivery System Reforms
Emerging payment and delivery reforms (often called “alternative payment models” or “value-based payment” designs) hold promise in advancing the efficient delivery of high-quality, personalized care.
Principles for Responsible Clinical Trial Data Sharing
Biopharmaceutical companies are committed to enhancing public health through responsible sharing of clinical trial data.
PhRMA Principles for Responsible Clinical Trial Data Sharing Certifications
In July 2013, members of PhRMA and the European Federation of Pharmaceutical Industries and Associations (EFPIA) adopted Principles for Responsible Clinical Trial Data Sharing.
PhRMA Principles on Clinical Pathway Programs
Healthcare providers and payers are increasingly turning to clinical pathways as tools to manage the cost of care and promote evidence-based treatment.
Principles for Value Assessment Frameworks
PhRMA supports the use of sound evidence for informed decision-making in health care.